A MarketsandMarkets report forecasts that the global biosimilars market will be worth $1.95 billion by 2018. Insulin, filgrastim and other recombinant protein products hold the biggest share of the market, but monoclonal antibodies are expected to be the fastest-growing segment. The Asia-Pacific region, which accounts for 29% of the global market, is forecast to grow the fastest, while the U.S. is waiting on the FDA to write regulations establishing a pathway for biosimilar reviews.
Report: Global biosimilars market could approach $2B in 5 years
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||